ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly

Laura Fabbri^{1

2}, Julien Guiot^{3

4}, Marie Vermant⁵, Ewa Miądlikowska⁶, Deborah Estrella⁷, Marlies S Wijsenbeek⁸, Wim Wuyts⁵, Elena Bargagli⁹, Antoine Froidure¹⁰, Paolo Spagnolo¹¹, Marcel Veltkamp^{12

13}, Maria Molina-Molina¹⁴, Cormac McCarthy¹⁵, Katerina Antoniou¹⁶, Michael Kreuter¹⁷, Catharina C Moor⁸

Affiliations

¹ Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial College, London, UK.
² Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
³ Department of Respiratory Medicine, University Hospital of Liège, Liège, Belgium.
⁴ GIGA I3 Research Group, Laboratory of Respiratory Medicine, Vascular and Interstitial Lung Disease Unit and Fibropole Research Group, University of Liège, Liège, Belgium.
⁵ Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
⁶ Department of Pneumology, Medical University of Lodz, Lodz, Poland.
⁷ Hospital das Clínicas, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
⁸ Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
⁹ Respiratory Diseases Unit, Department Medical Sciences, Surgery and Neurological Sciences, Siena University, Siena, Italy.
¹⁰ Pulmonology Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
¹¹ Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
¹² ILD Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.
¹³ Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
¹⁴ ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, CIBERES, Barcelona, Spain.
¹⁵ UCD School of Medicine, Education and Research Centre, St Vincent's University Hospital, Dublin, Ireland.
¹⁶ Laboratory of Molecular and Cellular Pneumonology, Dept of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, Greece.
¹⁷ Mainz Center for Pulmonary Medicine, Department of Pneumology, ZfT, Mainz University Medical Center and Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.

PMID: 38529351
PMCID: PMC10962449
DOI: 10.1183/23120541.00839-2023

ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly

Laura Fabbri et al. ERJ Open Res. 2024.

. 2024 Mar 25;10(2):00839-2023.

doi: 10.1183/23120541.00839-2023. eCollection 2024 Mar.

Authors

Affiliations

¹ Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial College, London, UK.
² Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy's and St Thomas' NHS Foundation Trust, London, UK.
³ Department of Respiratory Medicine, University Hospital of Liège, Liège, Belgium.
⁴ GIGA I3 Research Group, Laboratory of Respiratory Medicine, Vascular and Interstitial Lung Disease Unit and Fibropole Research Group, University of Liège, Liège, Belgium.
⁵ Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
⁶ Department of Pneumology, Medical University of Lodz, Lodz, Poland.
⁷ Hospital das Clínicas, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
⁸ Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
⁹ Respiratory Diseases Unit, Department Medical Sciences, Surgery and Neurological Sciences, Siena University, Siena, Italy.
¹⁰ Pulmonology Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
¹¹ Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy.
¹² ILD Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.
¹³ Division of Heart and Lungs, University Medical Center, Utrecht, The Netherlands.
¹⁴ ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, CIBERES, Barcelona, Spain.
¹⁵ UCD School of Medicine, Education and Research Centre, St Vincent's University Hospital, Dublin, Ireland.
¹⁶ Laboratory of Molecular and Cellular Pneumonology, Dept of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, Greece.
¹⁷ Mainz Center for Pulmonary Medicine, Department of Pneumology, ZfT, Mainz University Medical Center and Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.

PMID: 38529351
PMCID: PMC10962449
DOI: 10.1183/23120541.00839-2023

Abstract

This article summarises a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the International Congress of the European Respiratory Society in 2023. Translational and clinical studies focused on the whole spectrum of ILDs, from (ultra)rare ILDs to sarcoidosis, ILDs associated with connective tissue disease and idiopathic pulmonary fibrosis. The main topics of the 2023 Congress presentations were improving the diagnostic process of ILDs, better prediction of disease course and investigation of novel treatment options.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L. Fabbri, J. Guiot and E. Bargagli have nothing to disclose. Conflict of interest: M. Vermant reports travel fees from Sanofi, outside the submitted work. Conflict of interest: E. Miądlikowska reports travel fees from Boehringer Ingelheim, outside the submitted work. Conflict of interest: D. Estrella reports travel fees from Sanofi and Roche/Genentech outside the submitted work. Conflict of interest: M.S. Wijsenbeek reports grants from Boehringer Ingelheim and Hoffmann la Roche, and fees from Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, Hoffman la Roche, Horizon Therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, Respivant and CSL Behring, outside the submitted work, paid to her institution. Conflict of interest: W. Wuyts reports grants and fees from Boehringer Ingelheim, Hoffman la Roche, Galapagos and Sanofi, outside the submitted work, paid to his institution. Conflict of interest: A. Froidure reports grants and fees from Boehringer Ingelheim. Conflict of interest: P. Spagnolo reports grants from PPM Services, Roche and Boehringer Ingelheim, outside the submitted work, paid to his institution; and fees from PPM Services, Novartis, Pieris, Glycocore Pharma, Galapagos, Boehringer Ingelheim and Menarini outside the submitted work. Conflict of interest: M. Veltkamp reports fees from Boehringer Ingelheim and Chiesi outside the submitted work. Conflict of interest: M. Molina-Molina reports grants and fees from Boehringer Ingelheim, Roche, Chiesi and Ferrer, outside the submitted work. Conflict of interest: C. McCarthy reports grants and fees from Boehringer Ingelheim, Savara Inc., AI Therapeutics and Theravance Inc., outside the submitted work. Conflict of interest: K. Antoniou reports grants and fees from Boehringer Ingelheim, Hoffmann la Roche, GlaxoSmithKline, AstraZeneca, Chiesi and Menarini outside the submitted work. Conflict of interest: M. Kreuter reports grants and fees from Boehringer Ingelheim, Hoffman la Roche and Nichtraucherhelden/Sanero outside the submitted work. Conflict of interest: C.C. Moor reports grants and fees from Boehringer Ingelheim, Hoffmann la Roche, AstraZeneca and Daiichi Sankyo, outside the submitted work, paid to her institution.

Figures

**FIGURE 1**
Overview of the main topics for interstitial lung disease (ILD) at the European Respiratory Society (ERS) Congress 2023. PROMs: patient reported outcome measures.

See this image and copyright information in PMC

References

1. Guler SA, Cuevas-Ocaña S, Nasser M, et al. . ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Res 2022; 8: 00640-2021. doi:10.1183/23120541.00640-2021 - DOI - PMC - PubMed
1. Karampitsakos T, Diep PP, Loth DW, et al. . ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Res 2023; 9: 00584-2022. doi: 10.1183/23120541.00584-2022 - DOI - PMC - PubMed
1. Justet A, Ravaglia C, Zhao A, et al. . Spatial transcriptomic analysis reveals similar gene expression patterns in the long COVID and IPF lungs. Eur Respir J 2023; 62: Suppl. 67, OA4198. doi:10.1183/13993003.congress-2023.OA4198 - DOI
1. Bell J, Eyres M, Davies E, et al. . Defining and modelling the fibrotic niche in lung fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4197. doi:10.1183/13993003.congress-2023.OA4197 - DOI
1. Khan P, Blumer S, Savic S, et al. . A 3D organoid model mimicking honeycomb cysts in idiopathic pulmonary fibrosis. Eur Respir J 2023; 62: Suppl. 67, OA4204. doi:10.1183/13993003.congress-2023.OA4204 - DOI

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly

Affiliations

ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources